Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Behavioural Pharmacology|January 31, 2009
Relative potency and effectiveness of flunitrazepam, ethanol, and beta-CCE for disrupting the acquisition and retention of response sequences in ratsStuart T Leonard, Lisa R Gerak, Marcus S Delatte, et al.
Psychopharmacology|May 13, 2008
Interactions between Delta(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: discrimination and antinociceptionJun-Xu Li, Lance R McMahon, Lisa R Gerak, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 24, 2002
Discriminative stimulus effects of benzodiazepine (BZ)(1) receptor-selective ligands in rhesus monkeysLance R McMahon, Lisa R Gerak, Lawrence Carter, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 8, 2018
Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus MonkeysDavid R Maguire, Lisa R Gerak, James H Woods, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 23, 2018
Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel <i>μ</i>-Opioid Receptor Antagonist Methocinnamox in Rhesus MonkeysLisa R Gerak, David R Maguire, James H Woods, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 22, 2019
OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse PreventionDavid R Maguire, Lisa R Gerak, Gerta Cami-Kobeci, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 7, 2020
Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeysDavid R Maguire, Lisa R Gerak, Jesus J Sanchez, et al.
Psychopharmacology|August 22, 2020
Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy µ opioid receptor agonist and a δ opioid receptor antagonistSanjana Mada, Lisa R Gerak, Amélie Soyer, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 24, 2019
Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of <i>µ</i>-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in RatsLisa R Gerak, Vanessa Minervini, Elizabeth Latham, et al.
Behavioural Pharmacology|August 10, 2022
OREX-1038: a potential new treatment for pain with low abuse liability and limited adverse effectsLisa R Gerak, David R Maguire, Gerta Cami-Kobeci, et al.
Pageof 6